Citadel Advisors
AKTS

Citadel Advisors’s Aktis Oncology AKTS Stock Holding History

Citadel Advisors’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
+75,000
New +$1.46M ﹤0.01% 6980

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors's AKTS Position: Q1 2026 in Review

Citadel Advisors opened a new position in Aktis Oncology (AKTS) in Q1 2026: 75,000 shares worth $1.34M. The stake represents ﹤0.01% of the portfolio and ranks #6980 among its holdings.

69 funds tracked by Wall St. Rank hold AKTS as of Q1 2026.

  • Citadel Advisors held 75,000 shares of Aktis Oncology worth $1.34M as of Q1 2026.
  • Aktis Oncology was a new Citadel Advisors position in Q1 2026.
  • Aktis Oncology made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6980 holding.
  • 69 funds tracked by Wall St. Rank held Aktis Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.